DNCB Test in Cancer Patients

L. Sadoff, M. Glovsky, A. Alenty, W. J. Catalona, P. T. Taylor, P. B. Chretien

Research output: Contribution to journalLetter

3 Scopus citations

Abstract

To the Editor: The need for a standardized method of interpreting the DNCB skin test in patients with cancer was recently stressed by Catalona et al.1 Their unique approach in grading response is appealing, but may not represent an optimum method for detecting sensitization to DNCB. In testing over 50 patients with advanced cancer with DNCB, we used 1000 μg for initial sensitization, followed in two to three weeks with rechallenge doses of both 100 μg and 1000 μg. A majority of patients (75 per cent) reacted to the larger rechallenge dose, but very few (15 per cent) to a.

Original languageEnglish (US)
Pages (from-to)47-48
Number of pages2
JournalNew England Journal of Medicine
Volume287
Issue number1
DOIs
StatePublished - Jul 6 1972

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'DNCB Test in Cancer Patients'. Together they form a unique fingerprint.

  • Cite this

    Sadoff, L., Glovsky, M., Alenty, A., Catalona, W. J., Taylor, P. T., & Chretien, P. B. (1972). DNCB Test in Cancer Patients. New England Journal of Medicine, 287(1), 47-48. https://doi.org/10.1056/NEJM197207062870117